Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers
Yoshihisa Kobayashi(Harvard University), Pasi A. Jänne(Dana-Farber Cancer Institute), Jamie L. Hutchins(Guardant (United States)), Magda Bahcall(Harvard University), Lesli A. Kiedrowski(Guardant (United States)), Fangxin Hong(Dana-Farber Cancer Institute), Prafulla C. Gokhale(Georgetown University), Kristin S. Price(Guardant (United States)), Zihan Wei(The People's Hospital of Guangxi Zhuang Autonomous Region), Chhayheng Chhoeu(Boston University), Jiaqi Li(Dana-Farber Cancer Institute), Aaron Hardin(Guardant (United States))
Cited by 62
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k